Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 1

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 1
---
 or voting instruction card regarding each of these voting options. We are also pleased to furnish proxy materials to stockholders primarily over the Internet. This process expedites stockholders’ receipt of proxy materials, while lowering the costs of our Annual Meeting and conserving natural resources. On or around April 25, 2025, we will mail our stockholders a notice containing instructions on how to access our proxy materials and Annual Report for the fiscal year ended December 31, 2024 and vote online. The notice also provides instructions on how to vote online, by phone or by mail, and includes instructions on how you can receive a paper copy of proxy materials by mail. At this year’s Annual Meeting, the agenda includes the following proposals:

| Proposal                                                                                      |     | Board          
 Recommendation |
| Election of Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D. as Class II directors       |     | FOR            |
| To approve, on a non-binding advisory basis, the compensation of our named executive officers |     | FOR            |
| Ratification of Ernst & Young LLP as our independent registered public accounting firm        |     | FOR            |

Thank you for your ongoing support of and continued interest in PMV Pharmaceuticals. Sincerely, David H. Mack, Ph.D. President, Chief Executive Officer and Director

TABLE OF CONTENTS

PMV PHARMACEUTICALS, INC. 400 Alexander Park Drive, Suite 301 Princeton, New Jersey 08540 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 5, 2025

| Time and Date                                    
 Place                                            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  10:00 a.m., Eastern, on Thursday, June 5, 2025. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       www.virtualshareholdermeeting.com/PMVP2025 |     |                                                                                                                                                                                                                       |
|:-------------------------------------------------|:----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------:|:----|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Items of Business                                |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1. |     | To elect two Class II directors, Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D., to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified; |
|                                                  |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2. |     | To approve,